Netherlands Cancer Insitute
🇳🇱Netherlands
- Country
- 🇳🇱Netherlands
- Ownership
- Private
- Established
- 1913-10-10
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.nki.nl
The Radium-select Study
Not Applicable
Recruiting
- Conditions
- mCRPCMale Urogenital Diseases
- First Posted Date
- 2024-10-26
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 60
- Registration Number
- NCT06659926
- Locations
- 🇳🇱
NKI-AVL, Amsterdam, Noord-Holland, Netherlands
🇳🇱Meander Medisch Centrum, Amersfoort, Utrecht, Netherlands
🇳🇱Sint Antonius ziekenhuis, Nieuwegein, Utrecht, Netherlands
The Diagnostic Value of FAPI PET/CT in Staging of Newly Diagnosed Prostate Cancer
Not Applicable
Not yet recruiting
- Conditions
- Prostate CancerProstate Cancer Metastatic
- First Posted Date
- 2024-10-09
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 30
- Registration Number
- NCT06634173
Earlier Detection and Optimization of Treatment and Prognosis for Patients With Early-onset Colorectal Cancer
Recruiting
- Conditions
- Early-onset Colorectal Cancer
- First Posted Date
- 2024-08-23
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 300
- Registration Number
- NCT06568679
- Locations
- 🇳🇱
Netherlands Cancer Institute, Amsterdam, Noord-Holland, Netherlands
Feasibility of Primer Shot Radiotherapy for Non-small Cell Lung Cancer - PRIMER
Not Applicable
Recruiting
- Conditions
- Patients With Non-small-cell Lung Cancer
- First Posted Date
- 2024-07-30
- Last Posted Date
- 2025-01-06
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 34
- Registration Number
- NCT06528743
- Locations
- 🇳🇱
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting, Amsterdam, Netherlands
OPTImaL:Optimisation of Treatment for Patients With Low Stage Triple-negative Breast Cancer With High Stromal Tumor-infiltrating Lymphocytes
Recruiting
- Conditions
- Breast Cancer Stage ITriple Negative Breast Cancer (TNBC)
- Interventions
- Other: No adjuvant chemotherapyDrug: Adjuvant chemotherapy
- First Posted Date
- 2024-06-26
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 490
- Registration Number
- NCT06476119
- Locations
- 🇳🇱
Zuyderland Medisch Centrum, Sittard-Geleen, Limburg, Netherlands
🇳🇱Medical spectrum Twente, Enschede, Overijssel, Netherlands
🇳🇱Noordwest Ziekenhuisgroep, Alkmaar, Netherlands
Preoperative Accelerated Partial Breast Irradiation in Patients with Locally Recurrent or Second Primary Breast Cancer
Not Applicable
Recruiting
- Conditions
- Breast Cancer
- First Posted Date
- 2024-04-12
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 31
- Registration Number
- NCT06362616
- Locations
- 🇳🇱
The Netherlands Cancer Institute, Amsterdam, Netherlands
Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile Cancer
Phase 2
Recruiting
- Conditions
- Urologic NeoplasmsPenile Squamous Cell CarcinomaUrogenital NeoplasmsPenile CancerLocally Advanced Penile CarcinomaMale Urogenital Diseases
- Interventions
- Drug: Carboplatin/PaclitaxelProcedure: Partial or total penectomy with inguinal and/or pelvic lymph node dissection
- First Posted Date
- 2024-04-09
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 27
- Registration Number
- NCT06353906
- Locations
- 🇳🇱
NKI-AVL, Amsterdam, Noord-Holland, Netherlands
NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 Trial
Phase 2
Recruiting
- Conditions
- Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2024-04-02
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 60
- Registration Number
- NCT06342037
- Locations
- 🇳🇱
Antoni van Leeuwenhoek, Amsterdam, Noord-Holland, Netherlands
Distributed Learning of Edic and CardIac Dose Effects in Lung Cancer
Not yet recruiting
- Conditions
- NSCLC
- First Posted Date
- 2024-03-26
- Last Posted Date
- 2024-03-26
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 20000
- Registration Number
- NCT06329648
A Pilot Study of Dose dE-eScalaTion IN prostATe radIOtherapy usiNg the MRL
Not Applicable
Active, not recruiting
- Conditions
- Prostate Cancer
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 20
- Registration Number
- NCT06284304
- Locations
- 🇳🇱
Netherlands Cancer Institute, Amsterdam, Netherlands